Our Front-runner: KZR-616

First-in-Class Selective Immunoproteasome Inhibitor

KZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition. Playing a critical role in the body's immune system, the immunoproteasome is abundantly expressed in immune cells and acts as a master regulator of multiple cellular functions. By selectively inhibiting the immunoproteasome, KZR-616 has the potential to affect multiple drivers of immune-mediated diseases.

Learn more about the science behind immunoproteasome inhibition.

A Pipeline in A Drug

With its broad immunomodulatory capabilities, KZR-616 has broad therapeutic potential for those living with autoimmune diseases. KZR-616 is active in a number of animal models of autoimmune diseases and supported by compelling early clinical data, KZR-616 offers a “pipeline in a drug” with the potential to disrupt the treatment paradigm in a wide array of immune-mediated and autoimmune diseases.  

Clinical Trials

The MISSION Phase 1b trial, which is evaluating the safety, tolerability and early efficacy signals in patients with lupus with and without nephritis, has completed enrollment. Data gathered to date support the development of KZR-616 as a chronic therapy for a wide range of severe, chronic autoimmune diseases and immune-mediated disorders. Phase 2 clinical trials are currently underway in lupus nephritis and dermatomyositis/polymyositis.

Find out more about our Clinical Trials with KZR-616

Our Therapeutic Potential Goes the Distance

We are leveraging KZR-616’s broad immuno-modulatory potential to initially study severe, chronic autoimmune diseases – including lupus nephritis and idiopathic inflammatory myopathies such as polymyositis and dermatomyositis.

Lupus Nephritis

Lupus nephritis or, LN, is an inflammation of the kidney that is serious complication of the disease, systemic lupus erythematosus (lupus or SLE). SLE is a chronic, complex and oftentimes disabling autoimmune disorder whereby the body’s own immune system attacks itself. SLE predominantly affects women and is more prevalent in women of color. The Centers for Disease Control and Prevention estimates there are approximately 322,000 people living with SLE in the United States and the Lupus Foundation of America estimates up to 1.5 million people are living with a form of lupus in the U.S.. Approximately half those living with lupus will develop lupus nephritis at some point during their disease. The presence of nephritis dramatically increases mortality risk in lupus patients, and there are currently no FDA-approved therapies for lupus nephritis in the U.S and EU.

Polymyositis/ Dermatomyositis

Polymyositis (PM) and Dermatomyositis (DM) are two of the five types of autoimmune myositis diseases. Both are chronic, debilitating, inflammatory autoimmune myopathies that are distinguished by inflammation of the muscles as well as the skin (in DM). An estimated 30,000-120,000 people in the United States are living with these severe and progressive inflammatory myopathies that are characterized by marked morbidity and associated mortality.  While debilitating muscle weakness is the hallmark of these myopathies, including compromised muscles of respiration, other internal organ system dysfunctions can be equally disabling. The aim of treatment for these diseases is to suppress inflammation, increase muscle strength, and prevent long-term damage to muscles and extramuscular organs; however, treatment options are limited for DM, and there are currently no approved treatments for PM. For more information, please visit The Myositis Association.